RiboX (Shanghai) Therapeutics Co. Ltd – Trademark Portfolio
Entity Type: 99
RiboX (Shanghai) Therapeutics Co. Ltd holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include S and RIBOX. The owner is based in Shanghai.
Pudong New Area
No. 15, Lane 388, Shengrong Road
Shanghai 201203 , CN
Showing of trademarks Trademarks
Trademark Classifications
RiboX (Shanghai) Therapeutics Co. Ltd's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does RiboX (Shanghai) Therapeutics Co. Ltd have?
RiboX (Shanghai) Therapeutics Co. Ltd has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does RiboX (Shanghai) Therapeutics Co. Ltd file in?
RiboX (Shanghai) Therapeutics Co. Ltd files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are RiboX (Shanghai) Therapeutics Co. Ltd's most well-known trademarks?
RiboX (Shanghai) Therapeutics Co. Ltd's registered trademark portfolio includes well-known marks such as S and RIBOX. These are among 2 currently registered trademarks in the portfolio.
What is RiboX (Shanghai) Therapeutics Co. Ltd's trademark registration success rate?
RiboX (Shanghai) Therapeutics Co. Ltd has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.